Repurposing Drugs for Global Diseases
Reduced Cost, Diminished Risk, More Opportunity
At Algernon Pharmaceuticals, our capital-efficient drug development and repurposing strategy allows us to advance research programs in our pipeline at a much lower cost and risk than other new chemical entity research programs. Our lead candidates, NP-120 (Ifenprodil) and NP-251 (Repirinast) have not only gone through their pre-clinical phase, but since they are previously approved drugs, they have significant safety history in the patient populations they were developed to treat. While AP-188 (N,N-Dimethyltryptamine, or DMT) has never been approved, there have been several Phase 1 studies conducted confirming its safety as well.